9
Participants
Start Date
February 21, 2025
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Donor-derived CD123-CD16 bispecific antibody-modified NK cells
Patients enrolled sequentially received varying doses of NK cell infusions. The first three patients received 1×10⁷ cells/kg, the next three received 2×10⁷ cells/kg, and the final three received 4×10⁷ cells/kg.
RECRUITING
Chinese PLA General Hospital, Beijing
Chinese PLA General Hospital
OTHER
Chunji Gao
OTHER